DSIP 15mg — Research Protocol Reference

DSIP is administered via subcutaneous injection once daily in the evening, 30–60 minutes before intended sleep.

Dosing follows a structured titration from a low intro dose up to an active maintenance range, with a mandatory rest period after 12 weeks of use.

Do not use DSIP alongside benzodiazepines, Z-drugs, or other GABAergic compounds without medical guidance, as combined effects on the central nervous system are unpredictable.

⚠️ 3mL micro needle syringe is strongly recommended for the first 5 days of each cycle for precise low-volume measurement. ⚠️

DSIP has been studied at doses of 25mcg to 500mcg/day in human and animal research, with the strongest sleep architecture benefits documented in the 100–500mcg range. The titration approach, starting low and building across the first two weeks, reflects both documented tolerability data and the peptide's cumulative effect on GABAergic and HPA axis pathways. The 4-week rest period allows these systems to reset fully before repeating.

Each 15mg vial reconstituted at 3mL yields 5,000mcg/mL (1 unit = 50mcg), a single vial covers one full 12-week active cycle at mid-range dosing.

In biohacking forums, simplified protocols of 200–300mcg nightly for 14 days followed by a 2-week break are common for ongoing sleep maintenance. These are community-derived patterns, not clinical.

DSIP is injected subcutaneously once daily in the evening throughout the active phase. Timing relative to intended sleep is the single most important administration variable, the peptide's GABAergic and delta wave effects are time-sensitive and work best when sleep follows the injection within 30–60 minutes.

• 30–60 minutes before sleep: Inject at a consistent time each evening that allows you to be in bed within the hour. DSIP's mechanism is tied to sleep onset, dosing too early reduces effectiveness.
• Reduce light and screen exposure around dose: Blue light suppresses melatonin and competes with DSIP's sleep-onset signalling. Dim lighting and no screens for 30–60 minutes after injection significantly improves outcomes.
• Avoid stimulants within 4 hours: Caffeine, pre-workouts, and stimulant compounds directly antagonise DSIP's GABAergic activity. A 4-hour minimum gap between any stimulant and your evening injection is required.
• Fixed sleep and wake times: DSIP works best when the circadian rhythm is consistent. Irregular sleep schedules reduce the peptide's ability to entrain and deepen the slow-wave sleep cycle.
• Weeks 9–12 frequency reduction: The step-down to 3–5 sessions per week during maintenance is intentional, it preserves receptor responsiveness while sustaining the HPA and sleep architecture improvements built during the active phase.

• Micro needle syringe for Days 1–5: The 100mcg intro dose is 2 units on a standard U-100 syringe. This volume is too small to draw accurately with a standard insulin syringe. Use a 3mL micro needle syringe for the first 5 days of each cycle.
• Effects build across the cycle: DSIP's sleep-deepening and cortisol-normalising effects are cumulative. Most people notice a meaningful shift in sleep depth and morning recovery quality by days 7–10 rather than night one.
• No dependency or rebound: Unlike sedative sleep medications, DSIP does not produce physical dependency or rebound insomnia when the cycle ends. The rest period is for receptor reset, not withdrawal management.
• Do not combine in the same syringe: Draw and administer DSIP alone. Mixing with other peptides risks degradation and unpredictable pH interactions.
• Discard at 28–30 days post-reconstitution: Peptide potency degrades in solution even when refrigerated. Do not use beyond the 30-day window regardless of remaining volume.

Taking too much DSIP can increase side effects. Signs your dose may be too high:

• Excessive grogginess or morning sedation: DSIP should deepen sleep without leaving sedative hangover. If you feel heavily groggy the following morning, reduce by one dose step and hold for 3–5 days.
• Hypotension or light-headedness on waking: Documented at higher doses in some subjects. Reduce dose and ensure adequate hydration in the evening.
• Vivid or disturbing dreams: Delta wave amplification at high doses can intensify dreaming. Reduce to the previous dose step if dreams are disruptive.
• Injection site irritation: Persistent redness not resolving within 24 hours. Rotate sites more consistently and reduce dose volume.

If any of these occur, step back to the previous phase dose and hold for 3–5 days before advancing again.

A dose may be too low if expected effects are absent after consistent use. Common indicators:

• No improvement in sleep depth or continuity by days 7–10: If sleep quality feels unchanged at the end of the first titration week, confirm timing (30–60 min pre-sleep) and stimulant avoidance before adjusting dose.
• No change in morning recovery or energy by week 3: DSIP's cortisol-normalising effects typically produce noticeable improvements in daytime energy and stress resilience by the active phase. Absence suggests either underdosing or timing issues.
• No reduction in sleep onset time after 2 weeks: If you are still taking as long to fall asleep as before starting, review timing relative to sleep and confirm the cycle is light-restricted and stimulant-free.

If these indicators persist after a full active phase, advance to the upper end of the dose range (500mcg/6–10 units) and ensure all timing and lifestyle variables are in place before reassessing.

⚠️ This is for informational purposes only. For medical advice or diagnosis, consult a professional. ⚠️